Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome.
Gitlin
M J
MJ
D000328:Adult; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy*; D003511:Cyclohexanols / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D009207:Myoclonus / Q000139:chemically induced* / Q000175:diagnosis; D011985:Receptors, Serotonin / Q000187:drug effects*; D012642:Selegiline / Q000008:administration & dosage / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis*; D013577:Syndrome; D000069470:Venlafaxine Hydrochloride
D003511:Cyclohexanols; D008996:Monoamine Oxidase Inhibitors; D011985:Receptors, Serotonin; D012642:Selegiline; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride